Norroy Bioscience Opens New Research Institute in Nanjing, China
Jiangsu (China) | 01 April 2025
-
On December 25, 2024, Norroy Bioscience officially launched operations at its new research institute in Nanjing, China — a significant milestone in the company’s global R&D expansion.
Nanjing is a city known for its rich cultural heritage and strong scientific and educational resources. As one of the most dynamic hubs for innovative drug development in China, it offers a complete ecosystem for biopharmaceutical research, development, and commercialization.
The newly established Norroy Nanjing Research Institute plays a central role in the company’s innovation strategy. By leveraging the region’s strategic location and talent pool, the institute will serve as a hub for original molecule discovery, translational medicine, and clinical research in the field of radiopharmaceuticals. Its goal is to drive continuous innovation in precision diagnostics and targeted radionuclide therapy. -
The Nanjing institute will operate synergistically with Norroy’s testing center in Wuxi and its Class A manufacturing facility in Ma'anshan. Together, these sites will form an integrated network combining R&D, production, and regulatory capabilities — ensuring smooth clinical trial advancement and accelerating commercialization across multiple therapeutic pipelines.
With R&D and production centers now established across China and the U.S., Norroy Bioscience is building a globally oriented development strategy. The launch of the Nanjing institute further strengthens the company’s competitive edge in radiopharmaceutical innovation and reinforces its commitment to bringing “China-originated, globally impactful” therapies to patients worldwide.
Contact the Media Relations Department
This is the media section, we welcome inquiries from the media
bd@norroybioscience.com
